A61K 38/1719
Muscle proteins
Official title: {Muscle proteins, e.g. myosin or actin}
A61K38/1719 (Muscle proteins) appears on 53 US grants and 131 published applications in this corpus.
Search patents in A61K- Granted patents
- 53
- Published applications
- 131
- Assignees
- 84
- Inventors
- 221
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 1 | 3 |
| 2012 | 0 | 2 |
| 2013 | 0 | 4 |
| 2014 | 2 | 9 |
| 2015 | 2 | 5 |
| 2016 | 4 | 4 |
| 2017 | 3 | 9 |
| 2018 | 3 | 4 |
| 2019 | 7 | 16 |
| 2020 | 3 | 10 |
| 2021 | 8 | 9 |
| 2022 | 6 | 9 |
| 2023 | 3 | 14 |
| 2024 | 6 | 9 |
| 2025 | 4 | 15 |
| 2026 | 1 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Non-viral immuno-targeting1 Sep 2026US 12,721,900 B2University of Washington
- Ubiquitous antigens for treatment of autoimmune or inflammatory diseases26 Aug 2025US 12,397,038 B2UTI Limited Partnership
- Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy5 Aug 2025US 12,377,170 B2Research Institute At Nationwide Children's Hospital
- Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy29 Apr 2025US 12,285,497 B2Research Institute At Nationwide Children's Hospital
- Adeno-associated virus variant capsids and methods of use thereof11 Feb 2025US 12,221,616 B2AD Molecular Therapeutics Inc.
- Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy14 May 2026US 2026/0131032 A1Research Institute At Nationwide Children's Hospital
- Treatment of cardiomyopathy with aav gene therapy vectors2 Apr 2026US 2026/0091139 A1DiNAQOR AG
- Genetic constructs for gene editing5 Mar 2026US 2026/0061074 A1Sarepta Therapeutics, Inc.
- Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy29 Jan 2026US 2026/0027235 A1Research Institute At Nationwide Children's Hospital
- Ocular vectors and uses thereof8 Jan 2026US 2026/0007773 A1Aldevron, LLC
Most cited
By later US patents
- Means and methods for counteracting muscle disorders80US 9,243,245 B2Academisch Ziekenhuis Leiden · 2016
- Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA63US 9,528,109 B2Academisch Ziekenhuis Leiden · 2016
- Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene59US 9,499,818 B2Academisch Ziekenhuis Leiden · 2016
- Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA55US 9,926,557 B2Academisch Ziekenhuis Leiden · 2018
- Directed evolution and in vivo panning of virus vectors42US 8,632,764 B2The University of North Carolina at Chapel Hill · 2014